Insomnia News and Research

Latest Insomnia News and Research

Study establishes link between workplace bullying and increased sleep disturbances

A study in the Sept.1 issue of the journal SLEEP shows that current or past exposure to workplace bullying is associated with increased sleep disturbances. Associations also were found between observed bullying and sleep disruption, indicating that bullying has detrimental effects even when it is experienced indirectly.

1 Sep 2009

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

A study in the Sept.1 issue of the journal Sleep shows that the sleep-wake activity rhythms of breast cancer patients are impaired during the administration of chemotherapy. Results indicate that the first cycle of chemotherapy is associated with a temporary disruption of these rhythms, while repeated administration of chemotherapy results in progressively worse and more enduring impairments.

1 Sep 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

New sleep formula unveiled at USANA Health Sciences' 17th annual international convention

USANA Health Sciences, Inc. hosted thousands of independent Associates and guests from around the world this week for its 17th annual international convention in Salt Lake City.

30 Aug 2009

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation proves a suitable alternative to traditional benzodiazepine detoxification

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation (ABNR) involves a safe, medically-assisted withdrawal from Benzodiazepines in a hospital setting. This advanced approach to Benzodiazepine withdrawal offers patients another alternative to traditional benzodiazepine detoxification, which even when done gradually, can be extremely dangerous and even life threatening.

29 Aug 2009

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

Licensing agreement between Orexo and Novartis signed to develop and commercialise a novel product related to Orexo’s OX17 program

Orexo (STO: ORX) announces it has signed an exclusive worldwide licensing agreement with a Novartis affiliate to develop and commercialise a novel product related to Orexo’s OX17 program.

28 Aug 2009

Alexza completes acquisition of Symphony Allegro after sharholders' approval

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.

27 Aug 2009

Mutations associated with prion diseases are sufficient to cause transmissible neurodegenerative disease

For the first time, Whitehead Institute researchers have shown definitively that mutations associated with prion diseases are sufficient to cause a transmissible neurodegenerative disease.

26 Aug 2009

Lundbeck to launch Sabril in the US following FDA's NDA approval

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril® (vigabatrin) Tablets and Oral Solution. Lundbeck plans to launch Sabril in the United States in the third quarter.

24 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Transcept Pharmaceuticals' agreement with Purdue Pharmaceutical Products may lead to staff reduction

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced plans to reduce operating expenses by eliminating certain staff positions following its recently announced License and Collaboration Agreement with Purdue Pharmaceutical Products to commercialize Intermezzo((R) )(zolpidem tartrate sublingual tablet) in the United States.

19 Aug 2009

Cognitive behavioral therapy improves sleep and pain in osteoarthritis

A study in the Aug. 15 issue of the Journal of Clinical Sleep Medicine shows that the use of cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for older patients with osteoarthritis and comorbid insomnia.

16 Aug 2009

Major depressive disorder redefined

Researchers from Rhode Island Hospital's department of psychiatry propose that the definition for major depressive disorder (MDD) should be shortened to include only the mood and cognitive symptoms that have been part of the definition in the Diagnostic and Statistical Manual of Mental Disorders (DSM) for the past 35 years.

24 Jul 2009

Hepatitis C infection: Treatment options equally effective, likelihood of success known early on

Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.

22 Jul 2009

Sleep-disorded breathing and weight gain: The Sleep Heart Health Study

According to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, a link exists between the severity of obstructive sleep apnea (OSA) and weight gain.

12 Jun 2009

Snoring during pregnancy may mean greater risk for gestational diabetes

If you are pregnant and your mate complains your frequent snoring is rattling the bedroom windows, you may have bigger problems than an annoyed, sleep-deprived partner.

12 Jun 2009

Does sleep duration influence body mass index in twins?

Body Mass Index (BMI) varies as a function of habitual sleep duration, according to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.

12 Jun 2009

Sleep promotes lasting changes in memory for emotional scenes

According to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, sleep selectively preservers memories that are emotionally salient and relevant to future goals when sleep follows soon after learning. Effects persist for as long as four months after the memory is created.

12 Jun 2009

Sleep quality in women with rheumatoid arthritis

According to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, symptoms of Rheumatoid Arthritis (RA) negatively affect women's sleep. Sleep is further impaired by pain, depression and poor adherence to RA medications.

10 Jun 2009

Insomnia News and Research

Latest Insomnia News and Research

Study establishes link between workplace bullying and increased sleep disturbances

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

New sleep formula unveiled at USANA Health Sciences' 17th annual international convention

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation proves a suitable alternative to traditional benzodiazepine detoxification

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Licensing agreement between Orexo and Novartis signed to develop and commercialise a novel product related to Orexo’s OX17 program

Alexza completes acquisition of Symphony Allegro after sharholders' approval

Mutations associated with prion diseases are sufficient to cause transmissible neurodegenerative disease

Lundbeck to launch Sabril in the US following FDA's NDA approval

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Transcept Pharmaceuticals' agreement with Purdue Pharmaceutical Products may lead to staff reduction

Cognitive behavioral therapy improves sleep and pain in osteoarthritis

Major depressive disorder redefined

Hepatitis C infection: Treatment options equally effective, likelihood of success known early on

Sleep-disorded breathing and weight gain: The Sleep Heart Health Study

Snoring during pregnancy may mean greater risk for gestational diabetes

Does sleep duration influence body mass index in twins?

Sleep promotes lasting changes in memory for emotional scenes

Sleep quality in women with rheumatoid arthritis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Insomnia News and Research

Latest Insomnia News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in